This federal contract award is for the Small Business Innovation Research (SBIR) program. The contract was awarded to Kiyatec Inc., a for-profit organization, with a ceiling value of $1,704,285.58. The contract is a definitive contract with a firm fixed price pricing type. The ultimate completion date is November 1, 2019, and the award date was September 30, 2015. The contract was set aside for small businesses. The funding agency is the National Cancer Institute, a civilian agency. The contract...
<p>The National Cancer Institute (NCI) awarded a $249,792 Small Business Innovation Research (SBIR) Phase I contract to Biotex, Inc. to develop "Instruments and Devices that Preserve Molecular Profiles in Tumors" under SBIR Topic 257. The contract is a firm-fixed-price definitive contract with a period of performance ending on June 30, 2010. This SBIR contract supports the NCI's research objectives related to advancing cancer diagnostics and therapeutics.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Lineage Cell Therapeutics, Inc. for the development of high content screening of 3D cultured cancer cells. The contract has a ceiling value of $285,423 and is a definitive, firm fixed-price contract with a completion date of September 4, 2014. The contract is set aside for small businesses. No other subcontractors are mentioned in the provided information.
<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>
The National Cancer Institute awarded a Firm Fixed Price Definitive Contract to Vivo Biosciences, Inc. for the "SBIR PHASE I NEW 3D HUBIOGEL CULTURE SYSTEM FOR CANCER STEM CELLS EXPANSION & ANALYSIS" project. The contract has a ceiling value of $219,812.00 and the ultimate completion date is July 21, 2016. This is a Small Business Innovation Research (SBIR) Phase I contract, which supports early-stage research and development of innovative technologies. The contract does not have a...
<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Nanoscale Corporation for the development of a rapid in vitro screening assay to detect cancer biomarkers in urine and blood. The $150,000.00 firm-fixed-price contract has a completion date of May 2, 2013. This SBIR contract is part of the NCI's efforts to support small businesses in the development of innovative cancer-related technologies.</p>
<p>This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), a civilian federal agency, to Transgenex Nanobiotech Inc., a minority-owned small business, for the development of a "fibrous scaffold-induced spheroids mimicking TME" solution. The contract, valued at $299,992.00, is a definitive, firm fixed-price contract with a completion date of July 21, 2014. The contract was set aside for the participation of small businesses.</p>
<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Phase 2 contract worth $299,920.00 to Akrivis Technologies, LLC, a minority-owned, small disadvantaged business in Cambridge, MA. The contract, which is a definitive, firm-fixed-price contract, supports SBIR Topic 314 and has an ultimate completion date of October 21, 2016. The contract is set aside for total small business participation.</p>
This is a $189,094.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Angiocrine Bioscience, Inc., a for-profit organization. The contract is for the "SBIR PHASE I LARGE SCALE PROPAGATION OF CANCER CELLS USING THE VERAVEC PLATFORM IN AN AUTOMATED CLOSED SYSTEM" and was set aside for small businesses. The contract has an ultimate completion date of July 21, 2016 and was awarded on September 22, 2015. This appears to be a Small Business...
This $399,951 firm-fixed-price definitive contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to the small business Care Progress LLC. The contract supports the development of "BIOMARKERAWARE: A NOVEL SYSTEM TO IMPROVE PRECISION ONCOLOGY" under the NCI's Small Business Innovation Research (SBIR) program, which is a set-aside for small businesses. Care Progress LLC, a for-profit limited liability company, has previously...
The National Cancer Institute awarded a $294,719 Firm Fixed Price Definitive Contract to Kiyatec Inc., a small business, for the development of a 3D human tumor co-culture system to accurately predict clinical efficacy. This Small Business Innovation Research (SBIR) Phase I contract was awarded on September 20, 2013, with a completion date of July 21, 2014. The contract was awarded under Topic 314 and aims to create a novel in vitro testing platform to improve the prediction of actual clinical outcomes for cancer therapeutics.